Case Control Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. May 6, 2024; 12(13): 2173-2181
Published online May 6, 2024. doi: 10.12998/wjcc.v12.i13.2173
Clinical analysis of colistin sulfate in the treatment of pneumonia caused by carbapenem-resistant Gram-negative bacteria
Hai-Chang Xu, Yan Cui, Xue-Ying Wang, Hai-Bo Wu, Wei Li, Dan Wang, Na Lin, Lin Lin, Ying-Hui Zhang
Hai-Chang Xu, Yan Cui, Xue-Ying Wang, Hai-Bo Wu, Wei Li, Dan Wang, Na Lin, Lin Lin, Ying-Hui Zhang, Department of Intensive Care Medicine, The General Hospital of the Northern Theater Command of the People's Liberation Army of China, Shenyang 110016, Liaoning Province, China
Author contributions: Xu HC and Cui Y conceptualized the research project, wrote the paper and checked for scientific accuracy; Wang XY and Wu HB collected data and checked the manuscript for scientific accuracy; Li W and Wang D collected data, performed statistical analyses and checked the manuscript for scientific accuracy; Lin N, Lin L and Zhang YH collected data, performed statistical analyses and checked the manuscript for scientific accuracy.
Institutional review board statement: The study was approved by the Ethics Committee of the People's Liberation Army Northern Theater General Hospital (No: Y2024-016).
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: There are no conflicts of interest for any of the authors of this study.
Data sharing statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Cui, MM, Deputy Director, Department of Intensive Care Medicine, The General Hospital of the Northern Theater Command of the People's Liberation Army of China, No. 83 Wenhua Road, Shenhe District, Shenyang 110003, Liaoning Province, China. cyan9010@qq.com
Received: January 25, 2024
Peer-review started: January 25, 2024
First decision: February 8, 2024
Revised: February 27, 2024
Accepted: March 25, 2024
Article in press: March 25, 2024
Published online: May 6, 2024
Core Tip

Core Tip: Multidrug-resistant Gram-negative bacteria, exacerbated by excessive use of antimicrobials and immunosuppressants, are a major health threat. Colistin sulfate provides comprehensive, highly sensitive coverage against these bacteria. For pulmonary infections, its use via intravenous and nebulization methods improves cure rates and reduces adverse reactions, including renal and neurotoxicity. It also significantly ameliorates clinical symptoms in sepsis patients, proving to be safe and reliable.